Cognitive disorders in patients with chronic kidney disease: specificities of clinical assessment

Marion Pepin (1, 2) , Ana Carina Ferreira (3, 4) , Mustafa Arici (5) , Maie Bachman (6) , Michelangela Barbieri (7) , Inga Arune Bumblyte (8) , Sol Carriazo (9) , Pilar Delgado (10) , Liliana Garneata (11) , Konstantinos Giannakou (12) , Olivier Godefroy (13, 14) , Tomasz Grodzicki (15) , Aleksandra Klimkowicz-Mrowiec (15) , Justina Kurganaite (8) , Sophie Liabeuf (16, 14) , Carmen Antonia Mocanu (11) , Giuseppe Paolisso (7) , Goce Spasovski , Evgueniy Stefanov Vazelov (17) , Davide Viggiano (7) , Carmine Zoccali , Ziad A. Massy (1, 2) , Andrzej Wiecek (18)

1 Hôpital Ambroise Paré [AP-HP]
2 CESP - Centre de recherche en épidémiologie et santé des populations
3 Hospital Curry Cabral [Lisbon, Portugal]
4 NOVA - Universidade Nova de Lisboa = NOVA University Lisbon
5 Hacettepe University = Hacettepe Üniversitesi
6 TTÜ - Tallinn University of Technology
7 University of the Study of Campania Luigi Vanvitelli
8 LSMU - Lithuanian University of health Sciences
9 FJD - Fundacion Jimenez Diaz [Madrid]
10 UAB - Universitat Autònoma de Barcelona = Autonomous University of Barcelona = Universidad Autónoma de Barcelona
11 UMPCD - University of Medicine and Pharmacy “Carol Davila” Bucharest
12 European University of Cyprus
13 LNFP - Laboratoire de Neurosciences Fonctionnelles et Pathologies - UR UPJV 4559
14 CHU Amiens-Picardie
15 UJ - Uniwersytet Jagielloński w Krakowie = Jagiellonian University
16 MP3CV - Mécanismes physiopathologiques et conséquences des calcifications vasculaires - UR UPJV 7517
17 Medical University of Sofia [Bulgarie]
18 SUM - Medical University of Silesia

Neurocognitive disorders are frequent among chronic kidney disease (CKD) patients. Identifying and characterizing cognitive impairment (CI) can help to assess the ability of adherence to CKD risk reduction strategy, identify potentially reversible causes of cognitive decline, modify pharmacotherapy, educate the patient and caregiver and provide appropriate patient and caregiver support. Numerous factors are associated with the development and progression of CI in CKD patients and various conditions can influence the results of cognitive assessment in these patients. Here we review clinical warning signs that should lead to cognitive screening; conditions frequent in CKD at risk to interfere with cognitive testing or performance, including specificities of cognitive assessment in dialysis patients or after kidney transplantation; and available tests for screening and observed cognitive patterns in CKD patients.

Mots clés: chronic kidney disease; clinical assessment; cognitive impairment; cognitive screening test; comprehensive battery

Domaines: Urologie et Néphrologie; Sciences cognitives

Marion Pepin, Ana Carina Ferreira, Mustafa Arici, Maie Bachman, Michelangela Barbieri, et al.. Cognitive disorders in patients with chronic kidney disease: specificities of clinical assessment. Nephrology Dialysis Transplantation, 2022, 37 (2), pp.23-32. ⟨10.1093/ndt/gfab262⟩. ⟨hal-03578427⟩